Table 3.
Attribution of HPV positive HG-CIN and HPV positive ICC to HPV genotypes
| CIN2 n = 37 | CIN2/3 n = 31 | CIN3 n = 127 | AIS n = 1 | AIS + CIN3 n = 1 | HG-CIN n = 197 | HPV type | ICC n = 176 | SCC n = 145 | ADC n = 10 | ASC n = 9 | Other# n = 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.0 (45.9–51.4) | 44.9 (35.5–45.2) | 70.8 (59.8–71.7) | – | 100.0 (100.0–100.0) | 62.8 (53.3–63.5) | 16 | 72.1 (69.9–72.2) | 73.7 (71.0–73.8) | 50.0 (50.0–50.0) | 44.4 (44.4–44.4) | 91.7 (91.7–91.7) |
| 2.7 (2.7–2.7) | 6.5 (6.5–6.5) | 0.8 (0.8–0.8) | 100.0 (100.0–100.0) | – | 2.5 (2.5–2.5) | 18 | 10.8 (10.8–10.8) | 7.6 (7.6–7.6) | 40.0 (40.0–40.0) | 44.4 (44.4–44.4) | – |
| 8.5 (8.1–10.8) | 7.7 (3.2–9.7) | 5.9 (4.7–8.7) | – | – | 6.6 (5.1–9.1) | 31 | 1.7 (1.7–1.7) | 1.4 (1.4–1.4) | – | – | 8.3 (8.3–8.3) |
| – | 11.6 (9.7–12.9) | 9.3 (8.7–12.6) | – | – | 7.8 (7.1–10.2) | 33 | 5.7 (5.7–6.3) | 6.3 (6.2–6.9) | – | 11.1 (11.1–11.1) | – |
| – | – | 2.4 (2.4–2.4) | – | – | 1.5 (1.5–1.5) | 35 | 1.1 (1.1–1.1) | 1.4 (1.4–1.4) | – | – | – |
| 3.6 (2.7–5.4) | – | 0.0 (0.0–0.8) | – | – | 0.6 (0.5–1.5) | 39 | 0.6 (0.6–0.6) | 0.7 (0.7–0.7) | – | – | – |
| 2.7 (2.7–2.7) | 12.1 (9.7–12.9) | 0.0 (0.0–0.8) | – | – | 2.6 (2.0–3.0) | 45 | 3.4 (3.4–3.4) | 3.4 (3.4–3.4) | 10.0 (10.0–10.0) | – | – |
| 2.7 (2.7–2.7) | – | 0.9 (0.8–3.1) | – | – | 1.1 (1.0–2.5) | 51 | – | – | – | – | – |
| 7.2 (5.4–8.1) | 3.5 (3.2–6.5) | 2.7 (2.4–6.3) | – | – | 3.7 (3.0–6.6) | 52 | 0.6 (0.6–1.1) | 0.7 (0.7–1.4) | – | – | – |
| 0.0 (0.0–2.7) | 0.0 (0.0–3.2) | 1.6 (1.6–2.4) | – | – | 1.2 (1.0–2.5) | 56 | 0.6 (0.6–0.6) | 0.7 (0.7–0.7) | – | – | – |
| 5.4 (5.4–5.4) | – | 2.4 (2.4–3.1) | – | – | 2.6 (2.5–3.0) | 58 | 0.6 (0.6–1.1) | 0.7 (0.7–1.4) | – | – | – |
| – | 4.0 (3.2–6.5) | – | – | – | 0.6 (0.5–1.0) | 59 | – | – | – | – | – |
| 2.7 (2.7–2.7) | 3.2 (3.2–3.2) | 1.6 (1.6–2.4) | – | – | 2.1 (2.0–2.5) | 66 | 0.6 (0.6–0.6) | 0.7 (0.7–0.7) | – | – | – |
| – | 0.0 (0.0–3.2) | – | – | – | 0.0 (0.0–0.5) | 68/73 | 0.6 (0.6–1.1) | 0.7 (0.7–1.4) | – | – | – |
| 2.7 (2.7–2.7) | – | – | – | – | 0.5 (0.5–0.5) | 6* | – | – | – | – | – |
| – | – | – | – | – | – | 11* | – | – | – | – | – |
| – | – | – | – | – | – | 34* | – | – | – | – | – |
| – | – | – | – | – | – | 40* | – | – | – | – | – |
| 2.7 (2.7–2.7) | – | – | – | – | 0.5 (0.5–0.5) | 42* | – | – | – | – | – |
| – | – | – | – | – | – | 43* | – | – | – | – | – |
| 0.0 (0.0–2.7) | – | – | – | – | – | 44* | – | – | – | – | – |
| 2.7 (2.7–2.7) | 0.0 (0.0–3.2) | – | – | – | 0.5 (0.5–1.0) | 53* | 0.0 (0.0–0.6) | 0.0 (0.0–0.7) | – | – | – |
| 0.0 (0.0–2.7) | – | 0.0 (0.0–0.8) | – | – | 0.0 (0.0–1.0) | 54* | – | – | – | – | – |
| – | – | – | – | – | – | 70* | – | – | – | – | – |
| – | – | – | – | – | – | 74* | – | – | – | – | – |
Data are proportional attribution and minimal-maximal attribution ranges (in brackets) presented in %. Proportional attribution was computed according to frequency of the HPV type adjusted for multiple infections among the samples in the category of lesions. Minimal attribution was calculated as the percent of samples with single infection with the given type within the category of lesions. Maximal attribution was calculated as the percent of samples with certain HPV type as single and multiple infections within the category of lesions
HG-CIN high-grade cervical intraepithelial neoplasia, ICC invasive cervical cancer, CIN2 cervical intraepithelial neoplasia grade 2, CIN 2/3 cervical intraepithelial neoplasia grade 2/3, CIN3 cervical intraepithelial neoplasia grade 3, AIS adenocarcinoma in situ, AIS + − adenocarcinoma in situ + any HG-CIN, SCC squamous cell carcinoma, ADC cervical adenocarcinoma, ASC adenosquamous carcinoma. # includes: neuroendocrine, undifferentiated and microinvasive squamous carcinoma;*-Low Risk HPV types